All Conferences on Visiting Speakers Program in Oncology (VSPO)
(104 records)
Page 1 of 11Next>
Sort by :    
May 15, 2019

MANAGEMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA.

  • Review of treatment algorithms
  • Discuss the overall management of RCC patients
  • How to select the best first-line treatment for metastatic renal cancer patients
Dr. Michael B. Atkins
Apr 03, 2019

TARGETED THERAPY FOR LUNG CANCER

  • To present recent clinical trial evidence for targeted therapy in NSCLC
  • To demonstrate the utility of targeted therapy in the treatment of CNS metastases
  • To discuss best-practices for the integration ofpathological and molecular information inthe management of NSCLC patients with oncogenic drivers
Dr. David Ross Camidge
Mar 27, 2019

CURRENT AND FUTURE MULTIPLE MYELOMA MANAGEMENT STRATEGIES: WHERE ARE WE HEADING?

  • Assess latest MM data highlights and clinical trials recently presented at the American Society of Hematology (ASH, Dec. 2018)
  • Discuss MAYO best clinical approaches for managing high risk cytogenetic patients in the TI NDMM and RRMM setting
  • Explore future treatment approaches for TI NDMM and RRMM –what is likely to become available in imminent future?
Rafael Fonseca, MD
Dec 12, 2018

WHATS NEW-METASTATIC COLORECTAL CANCER

  • Understanding the Current Epidemiology & Environment in mCRC
  • Learning about new emerging treatments in mCRC, including the role of immunotherapy
  • Managing toxicities and sequence agents in mCRC
  • Assessing Clinical case studies in 3L mCRC
Michael A. Morse, MD, FACP, MHS
Nov 22, 2018

NEW THERAPEUTIC OPTIONS IN IMMUNO-ONCOLOGY RE: EFFICACY OF PD-1 / PD-L1 INHIBITORS FOR NSCLC

  • Learning the role of immunotherapy in NSCLC
  • Identifying appropriate NSCLC patients for immunotherapy
  • Role of PDL1 status in determining which immunotherapy treatment is best suitable in NSCLC patients
Pr. Benjamin Besse
Nov 21, 2018

VERSION EN FRANÇAIS: NEW THERAPEUTIC OPTIONS IN IMMUNO-ONCOLOGY RE: EFFICACY OF PD-1 / PD-L1 INHIBITORS FOR NSCLC

  • Learning the role of immunotherapy in NSCLC
  • Identifying appropriate NSCLC patients for immunotherapy
  • Role of PDL1 status in determining which immunotherapy treatment is best suitable in NSCLC patients
Pr. Benjamin Besse
Oct 30, 2018

SYSTEMIC TREATMENT FOR DIFFERENTIATED THYROID CANCER, WHERE ARE WE AND WHERE TO GO

  • Discuss and determine, along with the patient, the best time to start treatment
  • Explain the benefits and possible side effects to the patient
  • Manage treatment complications to minimize security side effects
Marcia Simpson Brose, MD PhD
Sep 26, 2018

RECENT UPDATES IN THE TREATMENT OF RELAPSED & REFRACTORY MULTIPLE MYELOMA

  • Understanding current standards of care in the management of newly diagnosed multiple myeloma
  • Understanding the factors of disease biology and patient characteristics that impact on treatment decisions in relapsed myeloma
  • Information on the evolving role of immunotherapy of multiple myeloma
Xavier Leleu, MD Ph.D
Apr 25, 2018

THE ROLE OF NOVEL THERAPIES IN THE MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

  • Understanding treatment options in the management of frontline CLL and how to approach patient selection
  • Integrate the emerging data into clinical practice when providing treatment options to patients in the management of relapsed CLL and how to sequence therapies
  • Share experience and gain knowledge on best practices of effective management of adverse events associated with treatment options
Steven E Coutré MD Hematologist/ Leukemia Specialist Professor of Medicine (Hematology) Stanford University Medical Center
Apr 19, 2018

WHAT’S NEW IN THE MANAGEMENT OF UROTHELIAL CANCER

Will discuss topic such as:
  • Intravesical management
  • Cystectomies indications
  • Promises of immunotherapy in this context
Yves Fradet, MD, FRCS(C) Urologist-Oncologist Professor Department of Surgery, Division of Urology Laval University Head of the Urology Department of the CHU de Québec
Cystectomies, immunotherapy

Go to page Next>

 

 

Copyright © 2002-2019 Continuing Professional Development (CPD) Office,
Faculty of Medicine, McGill University